Senseonics Holdings Future Growth
Future criteria checks 2/6
Senseonics Holdings is forecast to grow earnings and revenue by 18.9% and 33.5% per annum respectively while EPS is expected to grow by 25% per annum.
Key information
18.9%
Earnings growth rate
25.00%
EPS growth rate
| Medical Equipment earnings growth | 17.0% |
| Revenue growth rate | 33.5% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 15 Jul 2026 |
Recent future growth updates
Recent updates
Seeking Alpha • Jul 14
Senseonics: Implantable Sensor, Unsustainable Spend
Summary Senseonics Holdings is a Sell, with persistent concerns about cash burn, dilution, and lack of profitability. SENS's direct-to-consumer strategy and in-house commercialization have driven high SG&A, with 2026 cash burn projected up to $120 million on $60–64 million revenue. Gross margins improved to 58% in Q1, but sustained growth remains highly dependent on heavy investment and infrastructure buildout. Pipeline products Gemini (2027) and Freedom (2028) could boost adoption, but no near-term inflection in revenue/opex is evident. Read the full article on Seeking Alpha
Narrative Update • Jul 14
SENS: Future Margins And Revenue Mix Will Drive Upside Potential
The analyst price target for Senseonics Holdings has been revised lower by several dollars per share. Analysts cite updated assumptions on fair value, revenue growth, profit margins, and a reduced future P/E multiple as the key drivers of this change.
Narrative Update • Jun 30
SENS: Long-Duration CGM Data Will Support Future Margin Upside
Senseonics Holdings' updated analyst price target has moved lower by about $5.10 to $13.80, as analysts factor in revised expectations for fair value, revenue growth, profit margins, and future P/E assumptions following recent target cuts from several firms. Analyst Commentary Recent research updates on Senseonics Holdings focus on how its current trading level compares with revised views on fair value, revenue potential, profitability, and assumed P/E multiples.
Narrative Update • Jun 16
SENS: Long Wear CGM Execution Will Support Future Profitability Repricing Potential
Analysts have trimmed their average price target on Senseonics Holdings stock by a few dollars, citing updated expectations that reflect modest adjustments to revenue growth, profit margin, discount rate, and future P/E assumptions. Analyst Commentary Recent research updates on Senseonics Holdings highlight that even with lower price targets, some bullish analysts still see potential drivers that they believe could support the stock if the company executes on its plans.Narrative Update • Jun 02
SENS: Long Wear CGM Execution Will Drive Future Profitability And Repricing
The analyst price target for Senseonics Holdings has been reduced by $11, with analysts citing updated fair value estimates, a lower future P/E assumption, and recent Street research that reset targets at H.C. Wainwright, Stifel, and Lake Street. Analyst Commentary Recent Street research on Senseonics Holdings points to a reset in price targets that reflects updated fair value work, revised P/E assumptions, and refreshed views on execution risk and potential growth.Narrative Update • May 17
SENS: Long Wear CGM Adoption Will Drive Future Profitability And Repricing
Senseonics Holdings' consensus analyst price target has been reduced by several dollars, with analysts citing updated assumptions for revenue growth, profitability, and valuation multiples as key reasons for the lower fair value outlook. Analyst Commentary Even with the recent cuts to price targets, bullish analysts still see potential for Senseonics Holdings to create value if the company executes on its growth and profitability plans.Narrative Update • Apr 29
SENS: Long Wear CGM Adoption And AID Integration Will Drive Upside
Analysts have slightly adjusted their price target for Senseonics Holdings to $31.00, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E multiples, while keeping the overall fair value view steady. What's in the News First European launch of the Eversense 365 CGM system, described as the world’s first and only one year CGM, starting with patients in Sweden and with rollouts planned in Germany, Spain and Italy in the coming weeks (Key Developments).Narrative Update • Apr 13
SENS: Real World CGM Use And AID Access Will Drive Upside
Analysts have maintained their $31.00 price target on Senseonics Holdings, citing updated assumptions that now reflect slightly different discount rate, revenue growth, profit margin, and future P/E inputs in their models. What's in the News The board is asking stockholders to approve a change to the Certificate of Incorporation to increase authorized common shares to 140,000,000 from 70,000,000, with the meeting set for May 20, 2026 (Key Developments).Narrative Update • Mar 30
SENS: Long-Duration CGM Data Will Support Future Automated Delivery Upside
Analysts have modestly adjusted their price target on Senseonics Holdings to $18.92, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E, while keeping their overall fair value view steady. What's in the News New real world evidence data for the Eversense 365 CGM system reports an average transmitter wear time of 93.8% over one year, a mean Glucose Management Indicator of 7.14% and a mean Time in Range of 66% across 5,059 sensors used in the US, with over 75% of users reaching hypoglycemic targets (Key Developments).Narrative Update • Mar 16
SENS: Real World CGM Outcomes And AID Adoption Will Support Upside
Analysts have maintained their $31.00 price target on Senseonics Holdings, citing slightly higher assumed discount rates, a modest adjustment in expected revenue growth and profit margins, and a small shift in future P/E assumptions as the main factors behind their updated view. What's in the News New real world evidence data on more than 5,000 Eversense 365 sensors in US patients showed high adherence, a mean Glucose Management Indicator of 7.14% and Time in Range of 66%, with over 75% of users meeting hypoglycemia targets across a full year of use (Key Developments).Narrative Update • Mar 02
SENS: Long-Duration CGM Access Will Drive Future Automated Delivery Upside
Analysts have modestly adjusted their price target on Senseonics Holdings to $18.92 per share. This reflects slightly different assumptions on discount rate, revenue growth, profit margin and future P/E, while keeping their overall valuation view broadly unchanged.Narrative Update • Feb 16
SENS: Internalized Commercial Model And AID Launch Will Drive Long-Term Upside
Analysts have maintained their $31.00 price target on Senseonics Holdings, citing largely unchanged fair value assumptions, along with small adjustments to the discount rate, revenue growth, profit margin, and future P/E inputs. What's in the News Senseonics issued 2026 guidance, with expected full year global net revenue of about US$58 million to US$62 million, linked to the planned transition of Eversense commercialization from Ascensia starting January 1, 2026 (Corporate guidance).Narrative Update • Feb 02
SENS: Long-Duration CGM Execution Risk Will Set Up Future Upside Potential
Analysts have trimmed their 12 month target on Senseonics to US$15 from US$25, citing updated sales multiples on 2028 estimates and a higher 12% discount rate to reflect commercial execution risk following the recent stock split. Analyst Commentary Bullish Takeaways Bullish analysts still see upside potential at US$15, even after trimming the target from US$25.Narrative Update • Jan 18
SENS: Long-Duration CGM Share Gains Will Support Future Upside Potential
Analysts have trimmed their average price target on Senseonics to about $18.92. This reflects updated models that factor in lower sales multiples, a roughly 12% discount rate to account for commercial execution risk, and expectations around future product adoption and capital needs.Analysis Article • Jan 13
Senseonics Holdings, Inc.'s (NASDAQ:SENS) Share Price Could Signal Some Risk
You may think that with a price-to-sales (or "P/S") ratio of 9.9x Senseonics Holdings, Inc. ( NASDAQ:SENS ) is a stock...Narrative Update • Jan 04
SENS: Internalized Commercial Model Will Drive Long Term Upside Potential
Analysts have trimmed their price target on Senseonics Holdings to $15.00 from $25.00, citing updated long term growth assumptions, a higher perceived discount rate to reflect commercial execution risk, and the need for additional capital as the company internalizes commercial operations despite favorable physician feedback on Eversense and Gemini. Analyst Commentary Bullish analysts acknowledge the reduced price targets but emphasize that the stock still offers meaningful upside from current levels, with valuation supported by long term revenue growth expectations for Eversense and the upcoming Gemini platform.Narrative Update • Dec 21
SENS: Long-Duration CGM Share Gains Will Drive Future Upside Potential
Analysts have modestly reduced their price target on Senseonics Holdings to $15 from $25, reflecting updated sales multiple assumptions, a higher discount rate to account for commercial execution risk, and a more cautious view on funding needs as the company prepares to take commercial operations back in house. Analyst Commentary Street research reflects a mixed but engaged view on Senseonics, with valuation resets largely tied to updated sales assumptions, perceived execution risk, and the capital intensity of bringing commercialization back in house.Analysis Article • Dec 09
Is Senseonics Holdings (NASDAQ:SENS) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Narrative Update • Dec 07
SENS: Long-Duration CGM Share Gains Will Drive Future Upside Potential
Analysts have modestly reduced their average price target for Senseonics Holdings to about $18.92 per share from roughly $25.00. They cite recalibrated sales multiples, a slightly higher risk premium around commercial execution, and the need for additional capital as the company internalizes commercialization and invests in next-generation sensor platforms.Narrative Update • Nov 23
SENS: Market Share Gains Will Drive Long-Term Revenue Expansion
Analysts have revised their price target for Senseonics Holdings lower. They note that updated sales estimates and higher perceived commercial risk have led to a reduction from approximately $25 to below $19 per share.Narrative Update • Nov 03
SENS: Future Commercial Rollout Will Drive Diabetes Monitoring Adoption
Analysts have revised their price target for Senseonics Holdings downward from $28.60 to $25.33 per share, citing expected financial impacts from the company's assumption of commercial operations. This is balanced by continued optimism over the Eversense 365 system's market potential.Narrative Update • Oct 20
Continuous Glucose Monitoring Will Redefine Preventive Diabetes Care
Analysts have significantly increased their price target for Senseonics Holdings from $1.43 to $28.60. They cite growing confidence in the company's expanding product offerings and anticipated demand for its Eversense 365 sensor system.Narrative Update • Aug 08
Continuous Glucose Monitoring Will Redefine Preventive Diabetes Care
The downward revision in Senseonics Holdings’ price target reflects a combination of lowered future earnings multiples and a higher discount rate, resulting in the consensus fair value estimate declining from $1.55 to $1.41. What's in the News Senseonics Holdings completed a $50 million follow-on equity offering, issuing 100 million common shares at $0.50 per share with a $0.03 discount.
New Narrative • Mar 28
Eversense 365 Will Expand Patient Access With EU Launch
U.S. launch and future EU expansion of Eversense 365 could drive revenue growth through increased adoption and international market presence.Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 135 | -97 | N/A | N/A | 5 |
| 12/31/2027 | 98 | -120 | N/A | N/A | 7 |
| 12/31/2026 | 62 | -125 | N/A | N/A | 7 |
| 3/31/2026 | 41 | -87 | -77 | -75 | N/A |
| 12/31/2025 | 35 | -69 | -60 | -59 | N/A |
| 9/30/2025 | 29 | -64 | -56 | -55 | N/A |
| 6/30/2025 | 25 | -68 | -55 | -54 | N/A |
| 3/31/2025 | 24 | -74 | -59 | -56 | N/A |
| 12/31/2024 | 22 | -79 | -63 | -60 | N/A |
| 9/30/2024 | 22 | -80 | -64 | -61 | N/A |
| 6/30/2024 | 24 | -80 | -66 | -64 | N/A |
| 3/31/2024 | 23 | -81 | -71 | -71 | N/A |
| 12/31/2023 | 22 | -60 | -71 | -70 | N/A |
| 9/30/2023 | 20 | -32 | -73 | -72 | N/A |
| 6/30/2023 | 18 | -68 | -70 | -70 | N/A |
| 3/31/2023 | 18 | 57 | -66 | -66 | N/A |
| 12/31/2022 | 16 | 142 | -67 | -66 | N/A |
| 9/30/2022 | 15 | 215 | -61 | -61 | N/A |
| 6/30/2022 | 14 | 318 | -60 | -60 | N/A |
| 3/31/2022 | 13 | 34 | -60 | -60 | N/A |
| 12/31/2021 | 14 | -302 | -56 | -56 | N/A |
| 9/30/2021 | 14 | -489 | -53 | -53 | N/A |
| 6/30/2021 | 11 | -555 | -52 | -52 | N/A |
| 3/31/2021 | 8 | -382 | -55 | -55 | N/A |
| 12/31/2020 | 5 | -175 | -68 | -67 | N/A |
| 9/30/2020 | 10 | -109 | -94 | -94 | N/A |
| 6/30/2020 | 14 | -105 | -116 | -116 | N/A |
| 3/31/2020 | 18 | -129 | -136 | -135 | N/A |
| 12/31/2019 | 21 | -116 | N/A | -136 | N/A |
| 9/30/2019 | 20 | -87 | N/A | -125 | N/A |
| 6/30/2019 | 20 | -100 | N/A | -116 | N/A |
| 3/31/2019 | 19 | -101 | N/A | -100 | N/A |
| 12/31/2018 | 19 | -94 | N/A | -91 | N/A |
| 9/30/2018 | 15 | -103 | N/A | -83 | N/A |
| 6/30/2018 | 12 | -88 | N/A | -72 | N/A |
| 3/31/2018 | 9 | -68 | N/A | -65 | N/A |
| 12/31/2017 | 6 | -59 | N/A | -56 | N/A |
| 9/30/2017 | 4 | -53 | N/A | -50 | N/A |
| 6/30/2017 | 2 | -46 | N/A | -45 | N/A |
| 3/31/2017 | 1 | -46 | N/A | -42 | N/A |
| 12/31/2016 | 0 | -44 | N/A | -38 | N/A |
| 9/30/2016 | 0 | -43 | N/A | -36 | N/A |
| 6/30/2016 | 0 | -40 | N/A | -32 | N/A |
| 3/31/2016 | 0 | -36 | N/A | -28 | N/A |
| 12/31/2015 | 0 | -30 | N/A | -25 | N/A |
| 9/30/2015 | 0 | -26 | N/A | -22 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SENS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SENS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SENS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SENS's revenue (33.5% per year) is forecast to grow faster than the US market (12.8% per year).
High Growth Revenue: SENS's revenue (33.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SENS's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/17 22:54 |
| End of Day Share Price | 2026/07/17 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Senseonics Holdings, Inc. is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Miksic | Barclays |
| Gregory Chodaczek | B. Riley Securities, Inc. |
| Marie Thibault | BTIG |